Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca to Adopt Bina Technologies' Genome Analysis Software for R&D

NEW YORK (GenomeWeb) – AstraZeneca will use Bina Technologies' genome analysis software as an enterprise platform to support its development work across three therapeutic areas, the companies said today.

Under the collaboration agreement, the pharma company will adopt the Bina Genomic Management Solution (GMS) globally to support genomic data analysis and management as part of its development of drugs in oncology, cardiovascular and metabolic disease, respiratory disease, inflammation, and autoimmunity. AstraZeneca will also become the first member of the Bina Alliance Program.

Bina, which Roche acquired in December, will provide AstraZeneca with access to its scientific and engineering teams to further develop Bina GMS for pharmaceutical applications.

"Bina GMS is a powerful data analysis platform that will help AstraZeneca leverage more effectively genomic data across all phases of our research globally as we develop personalized therapies to treat complex diseases," Carl Barrett, vice president of translational oncology at AstraZeneca, said in a statement.